Checkpoint Therapeutics

Checkpoint Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. Its product portfolio includes CK-301, CK-101, CK-103, CK-302, and Anti-CAIX. The company was founded on November 10, 2014 and is headquartered in Waltham, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe Waivers remove requirement to conduct pediatric clinical studies to support cosibelimab marketing authorization applications in Europe

Checkpoint Therapeutics Receives Pediatric Investigational Plan Waivers for Cosibelimab from the European Medicines Agency and U.K. Medicines & Healthcare Products Regulatory Agency

Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022 Positive top-line results from registration-enabling study of cosibelimab in metastatic cutaneous squamous cell carcinoma announced in January 2022; BLA submission expected in 2022

Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights

WALTHAM, Mass., April 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the results of its pivotal trial of cosibelimab in metastatic cutaneous squamous cell carcinoma (cSCC) have been selected for poster presentation at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, to be held at McCormick Place, in Chicago, June 3-7, 2022. Positive topline data were previously announced in January 2022, and a Biologics License Application (BLA) submission for cosibelimab is planned for later this year.

Checkpoint Therapeutics Announces Data Presentation of Pivotal Trial Results of Cosibelimab to be Presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting

Clarus Therapeutics Holdings

XpresSpa Group

Time to sell these penny stocks? The post Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

Insiders Are Dumping These Penny Stocks, Look Out Below Or Buy The Dip?

Cosibelimab BLA submission to FDA for cutaneous squamous cell carcinoma is expected in late 2022, with MAA to the European Medicines Agency shortly thereafter. Cosibelimab regulatory applications are possible because of obtaining a confirmed objective response rate of 47.4% in patients with cutaneous squamous cell carcinoma.

Checkpoint Therapeutics: Potential Upside Based On Marketing Application Submissions

WALTHAM, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that members of Checkpoint's management team will participate in the two-day Fortress Biotech (“Fortress”) Virtual R&D Summit taking place on Tuesday, April 5, 2022 and Wednesday, April 6, 2022. The Summit will be hosted by the B. Riley Securities' Healthcare Equity Research team and will feature multiple programs from Fortress' diversified pipeline.

Checkpoint Therapeutics to Present at the Virtual Fortress Biotech R&D Summit Hosted by B. Riley Securities

WALTHAM, Mass., March 28, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the full-year ended December 31, 2021 and recent corporate highlights.

Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights

Checkpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline Results

Axsome Therapeutics

These two clinical-stage biotechs have major upcoming catalysts that could catapult their shares higher.

2 Biotech Stocks That Could Be 10-Baggers in 2022

WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Justin Walsh, Equity Research Analyst (Biotechnology), at the B. Riley Securities' Virtual Oncology Conference, taking place on Thursday, January 27, 2022, at 11:00 a.m. EST. Checkpoint management will also participate in one-on-one meetings during the conference.

Checkpoint Therapeutics to Participate in the B. Riley Securities' Virtual Oncology Conference

Checkpoint Therapeutics Inc (NASDAQ: CKPT) announced topline results from its registration-enabling clinical trial evaluating cosibelimab, administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (cSCC). The study met its primary endpoint, with cosibelimab demonstrating a confirmed objective response rate (ORR) of 47.4%.

Checkpoint Therapeutics' Cosibelimab Posts 47.4% ORR In Skin Cancer Patients

The stock price of Checkpoint Therapeutics Inc (NASDAQ: CKPT) increased by over 13% during intraday trading. This is why it happened.

Checkpoint Therapeutics Stock (CKPT): Why The Price Substantially Went Up Today

Based on its latest clinical trial data, this small-cap biotech could have a best-in-class treatment for advanced skin cancer on the way.

Why Checkpoint Therapeutics Stock Is Heating Up Today

WALTHAM, Mass., Jan. 25, 2022 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced positive topline results from its registration-enabling clinical trial evaluating the safety and efficacy of its anti-PD-L1 antibody, cosibelimab, administered as a fixed dose of 800 mg every two weeks in patients with metastatic cutaneous squamous cell carcinoma (“cSCC”).

Checkpoint Therapeutics Announces Positive Topline Results from the Registration-Enabling Trial of Cosibelimab in Metastatic Cutaneous Squamous Cell Carcinoma

WALTHAM, Mass., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced the initiation of the CONTERNO study, a global, randomized Phase 3 trial of cosibelimab in combination with pemetrexed and platinum chemotherapy for the first-line treatment of patients with non-squamous non-small cell lung cancer (NSCLC). The primary endpoint for the CONTERNO Phase 3 trial is overall survival (OS), and the study is designed to support full regulatory approvals worldwide.

Checkpoint Therapeutics Announces Initiation of CONTERNO Phase 3 Trial of Cosibelimab Combined with Chemotherapy in Patients with First-Line Non-Squamous Non-Small Cell Lung Cancer

Checkpoint Therapeutics expects to report top-line results before year-end, which could determine if Cosibelimab is ready for regulatory submission that could lead to an approval and commercial launch in 2023. Volatility has the share price, which is making big moves in both directions as we move closer to year-end. Investors need to have a game plan.

Checkpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data Readout

WALTHAM, Mass., Nov. 04, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the third quarter ended September 30, 2021.

Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results

WALTHAM, Mass., Sept. 22, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in a fireside chat hosted by Jennifer Kim, Vice President, Equity Research, at the 2021 Cantor Virtual Global Healthcare Conference, taking place on Monday, September 27, 2021, at 9:20 a.m. ET. Checkpoint management will also participate in one-on-one meetings during the conference. A live webcast of the fireside chat will be available on the Events page, located within the Investors section of Checkpoint's website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days following the meeting.

Checkpoint Therapeutics to Participate in the 2021 Cantor Virtual Global Healthcare Conference

NEW YORK, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced financial results for the second quarter ended June 30, 2021.

Checkpoint Therapeutics Reports Second Quarter 2021 Financial Results

Checkpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab Data

NEW YORK, July 08, 2021 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that James Oliviero, President and Chief Executive Officer, will participate in the Ladenburg Thalmann 2021 Healthcare Conference, taking place July 13-14, 2021. The company will present a corporate update on Wednesday, July 14, 2021, at 11:30 a.m. ET and will also participate in one-on-one meetings during the conference. A webcast of the company's presentation will be available on the Events page, located within the Investors section of Checkpoint's website, https://ir.checkpointtx.com/event-calendar/default.aspx, for approximately 30 days after the meeting.

Checkpoint Therapeutics to Participate in the Ladenburg Thalmann 2021 Healthcare Conference

Equillium Inc

Flexion Therapeutics

ReShape Lifesciences

While most of Wall Street focuses on large-cap and mega-cap stocks, as they provide a degree of safety and liquidity, many investors are limited in the number of shares they can buy.

4 Biotech and Life Sciences Stocks Trading Under $10 With Gigantic Upside Potential

One analyst becomes a fervent believer in the company's stock.

Why Checkpoint Therapeutics Skyrocketed Today

Antelope Enterprise Holdings

Aethlon Medical

American Software

Atomera

Clean Energy Fuels

CynergisTek

Impac Mortgage Holdings

Pubmatic

SPI Energy

The stock prices of AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, and IMH have noticeably gained today. The post AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, IMH Stock Prices Gain Intraday appeared first on Pulse 2.0.

AEMD, CTEK, AEHL, AMSWA, CKPT, CLNE, SPI, ATOM, PUBM, IMH Stock Prices Gain Intraday

Lordstown Motors

ResMed

Helix Energy Solutions Group

Home Point Capital

Morgan Stanley

Omnicell

Renewable Energy Group

Weatherford International PLC

With the trading day about halfway over, the markets were trading sideways yet again, and it seems like the major averages may be stuck on this plateau.

Lordstown, Morgan Stanley, ResMed and More Wednesday Afternoon Analyst Calls

News for Checkpoint Therapeutics Stock (CKPT)